3

Koreans Overdose on Diet Pills

http://english.chosun.com

Korea's use of slimming pills and appetite suppressants ranks near the top in the world despite an obesity rate of 3.5 percent, only a quarter of the OECD's average 14.6 percent. Production and import of obesity drug Sibutramine rose 11 times from W4.4 billion in 2003 to W49 billion in 2008 (US$1=W1,140). The market for psychotropic appetite suppressants, which are categorized as narcotics by the International Narcotics Control Board, also grew four-fold. It is a paradox that one of the skinniest countries in the world consumes the largest amount of diet drugs. In a survey of 1,000 Koreans aged 15 to 59 by Consumers Korea, 86 percent had gone or were on a diet in 2008, while 13 percent said they had resorted to diet pills. The problem is that even people with average weight take diet pills and doctors prescribe them recklessly.

Read more »
3

FDA Panel to Review Vivus Anti-Obesity Drug

http://online.wsj.com

Vivus Inc. said a Food and Drug Administration advisory committee is tentatively set to review the company's new-drug application for its experimental Qnexa obesity treatment. Chief Executive Leland Wilson said the July 15 review will mark a critical milestone for Qnexa and the company. Vivus is one of three drug developers hoping to get regulatory approval of new oral obesity treatments, along with Orexigen Therapeutics Inc. and Arena Pharmaceuticals Inc. Vivus earlier this year also said that Qnexa was shown to reduce sleep apnea, when breathing stops briefly during sleep, by 69% in a midstage trial. While the sleep-apnea data were preliminary and based on a small set of patients, the results could help Qnexa eventually become the first drug for the condition, currently treated only by devices, and may further bolster Vivus's resume in its search for a large pharmaceutical company partner for the antiobesity drug. Vivus would need FDA approval to market a drug for that use.

Read more »
3

FDA to Review VIVUS Drug

http://www.zacks.com

announced that the New Drug Application (NDA) for its obesity candidate, Qnexa, will be reviewed by the Endocrinologic and Metabolic Drugs advisory committee of the U.S. Food and Drug Administration (FDA) tentatively on July 15, 2010. The US regulatory authority accepted the NDA filed by VIVUS for Qnexa on March 1, 2010. The NDA was filed in December 2009. A response from the FDA should be out in the fourth quarter of 2010 (action date: Oct 28, 2010). Even though the US agency is not bound to follow the advice of its advisory committees, the recommendation of the panel is usually considered by the agency while deciding on the fate of a drug candidate. Qnexa is VIVUS’ lead pipeline candidate. It is a proprietary oral drug candidate that combines two previously approved products, topiramate and phentermine, to employ a dual mechanism to treat obesity. The drug is designed to address the excess appetite and high threshold for satiety that impact eating behavior. The full dose of Qnexa is a combination of 15mg phentermine and 92mg of a proprietary controlled release (CR) topiramate. Qnexa is being developed to treat other indications also.

Read more »

User login

Navigation




online spanish program spanish online classes social bookmarking : share news headlines and videos facebook starbucks nutrition ipad apps for kids best iphone app for weight loss baba ramdev yoga free download online spanish lessons

phentermine 37.5